Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab

Bevacizumab (Bev) is a humanized vascular endothelial growth factor monoclonal antibody that is used with chemotherapeutic drugs for the treatment of metastatic colorectal cancer (mCRC). Bev-induced hypertension (HT) is the most common adverse reaction during clinical practice. However, at present,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Tianshu, Jia, Hui, Wu, Qiong, Zhang, Yan, Ma, Qun, Yao, Dong, Gao, Xudong, Xie, Danni, Xu, Zihua, Zhao, Qingchun, Zhang, Yingshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283643/
https://www.ncbi.nlm.nih.gov/pubmed/35847929
http://dx.doi.org/10.3389/fonc.2022.829059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283643/
https://www.ncbi.nlm.nih.gov/pubmed/35847929
http://dx.doi.org/10.3389/fonc.2022.829059

Ejemplares similares